Kevin C. Mannix | Teva Pharmaceutical Industries Ltd. |
Kåre Schultz | Teva Pharmaceutical Industries Ltd. |
Brendan O'Grady | Teva Pharmaceutical Industries Ltd. |
Michael McClellan | Teva Pharmaceutical Industries Ltd. |
Randall S. Stanicky | RBC Capital Markets LLC |
Chris Schott | JPMorgan Securities LLC |
Esther Rajavelu | Oppenheimer & Co., Inc. |
David A. Amsellem | Piper Jaffray & Co. |
Ami Fadia | Leerink Partners LLC |
David Maris | Wells Fargo Securities LLC |
Liav Abraham | Citi Research |
Umer Raffat | Evercore Group LLC |
Aharon Gal | Sanford C. Bernstein & Co. LLC |
Good morning, ladies and gentlemen. Thank you for standing by and welcome to the third quarter 2018 financial results conference call. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. I must advise you this call is recorded today, on Thursday, November 1, 2018.